$COSM

Cosmos Health Inc. (NASDAQ: COSM) announced that its subsidiary, Cana Laboratories, secured five-year agreements with Target Pharma for 5.2 million units, increasing its orderbook to 32.7 million units, a 31% rise since June. The deals cover dermatology and anti-infective products, expanding Cana's therapeutic categories to 11. The company expects the division to generate over $10 million in annual profit at full capacity.

Cosmos Health Inc. (COSM) has engaged Prime Ledger Inc. to structure a tokenized financing for its CCX0722 weight management device, aiming to raise capital without issuing common stock. The company acquired the technology in June 2026 and expects to retain future cash flows. The initial structuring phase is targeted for completion in Q4 2026, but there is no guarantee the financing will be completed.

Cosmos Health (COSM) plans a non-dilutive, tokenized financing for CCX0722, a weight-management device, without issuing new shares. The company owns the IP and targets a $562B market by 2033. Financing details are not yet finalized.

Cosmos Health Inc. (NASDAQ: COSM) announced a new five-year contract with Viofar for manufacturing 2.5 million units of ROSARTIA, a cardiovascular drug. This increases Cana Laboratories' orderbook to 27.5 million units, enhancing cash flow visibility and expanding its manufacturing portfolio. The agreement strengthens Cosmos Health's position in cardiovascular pharmaceuticals.

Cosmos Health Inc. (NASDAQ:COSM) launched C-ScrubVet, an antimicrobial cleanser for animals, in the UK, targeting the $69 billion global animal health market. The product is certified under European standards and manufactured in-house. The company expects this to support its 2029 revenue guidance of $200.6 million, with expansion into additional European markets planned for Q4 2026.

SOC, HTZ, and COSM stocks fell to 52-week lows. SOC dropped 56% after a $450M offering plan. HTZ declined 1.5% due to price target cuts. COSM initially fell but closed up 5.54% after a $5M share buyback plan. SOC and HTZ have declined 73% and 56% this year, respectively, while COSM is down 64.48%.

Cosmos Health Inc. (NASDAQ: COSM) retired an $8M convertible note a year early, reducing debt and eliminating dilution. The company reported a 30% reduction in operating cash requirements and announced a $5M share repurchase program. Management highlighted record revenue growth and a strong liquidity position, including Bitcoin holdings in a gain position.

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway · Highest Q2 and H1 revenue in Com

Cosmos Health Inc. (COSM) signed an exclusive 5-year distribution agreement with Innova Healthcare for its Sky Premium Life supplements in Saudi Arabia. The deal includes an initial 126,000-unit order and expects over 5 million units in 5 years. Innova operates 250+ pharmacies and is backed by major investors. The Saudi nutraceuticals market is valued at $3.26B, growing to $5.96B by 2033.

Cosmos Health Inc. (COSM) reported a wider net loss of $6.09M in Q2 2026, up from $2.83M in Q2 2025, due to higher fair value expenses and interest costs, despite a 28.8% revenue increase to $18.99M. Adjusted EBITDA loss narrowed. The company expanded product lines and secured potential financing. Cash position was $2.44M. Shares fell 6.58% to $0.19.